AptamiR is developing breakthrough therapies based on the research of Craig Mello and Andrew Fire who won the 2006 Nobel Prize for Physiology or Medicine for the discovery of RNA interference.
Human obesity, Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD) are growing worldwide pandemics caused by sedentary lifestyle and excessive consumption of energy-dense foods rich in saturated lipids and carbohydrates.
Current medical treatments of obesity:
- have poor benefit-to-risk profiles
- fail to reach their long-term goals and
- do not meet patients’ expectations
There is currently no approved drug for the treatment of NAFLD.
TO REMOVE FAT ACCUMULATION IN THE HUMAN BODY
by developing Oligonucleotide Therapeutics (ONTs) which increase:
- lipid oxidation
- mitochondrial activity and
- energy expenditure
AptamiR Therapeutics, Inc., a biotechnology company founded in 2012, is focused on developing a revolutionary treatment for human obesity and related cardiometabolic disorders. Based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or the intestinal absorption of food, AptamiR is developing microRNA-targeted therapeutics that enhance lipid oxidation and thermogenesis, turning fat-storing white adipocytes into fat-burning adipocytes (so called brown-like, brite or beige).
MicroRNA analogs are attractive drug candidates for complex diseases like obesity, diabetes and NAFLD, as they simultaneously modulate the expression of gene networks (One Drug-Multiple Targets concept).
AptamiR is also developing original drug delivery systems that can specifically supply microRNA analogs to adipose tissues or other particular organs and tissues.
AptamiR’s distinctive model of virtual, outsourced, and cost-effective drug research and development has resulted in the achievement of several proof of concept milestones within a few years in operations: